title: Evaluation of the efficacy of prednisolone in early wheezing induced by rhinovirus or respiratory syncytial virus.
abstract: BACKGROUND
  The role of systemic corticosteroids in the treatment of early childhood wheezing in children is not clear.
  
  
  OBJECTIVE
  We sought to determine whether prednisolone is effective in rhinovirus-induced early wheezing.
  
  
  METHODS
  We conducted a controlled trial comparing oral prednisolone (2 mg/kg per day in three divided doses for 3 days) with placebo in 78 hospitalized children (mean age, 1.1 year; standard deviation, 0.7) experiencing their first or second episode of wheezing induced by rhinovirus or respiratory syncytial virus. Mixed viral infections were excluded. Our primary end point was the time until the patient was ready for discharge; secondary end points included oxygen saturation during hospitalization, duration of symptoms, occurrence of relapses during the next 2 months and blood eosinophil counts at discharge and 2 weeks later.
  
  
  RESULTS
  In multivariate regression analysis, prednisolone did not influence the time until ready for discharge, but it decreased relapses during the subsequent 2-month period in rhinovirus-affected children (prednisolone versus placebo, 22% versus 56%; odds ratio, 19.06; 95% confidence interval, 2.52-144.03; P = 0.004) and in children with blood eosinophils > or = 0.2 x 10/L (respectively, 24% versus 71%; odds ratio, 10.57; 95% confidence interval, 1.99-56.22; P = 0.006). Rhinovirus-affected children had more blood eosinophils on admission (mean, 0.44 versus 0.086 x 10/L), had a higher prevalence of atopy (44% versus 8%) and were older (mean, 1.4 versus 0.9 years, P < 0.001 for all) than respiratory syncytial virus-infected children.
  
  
  CONCLUSIONS
  Prednisolone reduced relapses during a 2-month period after first episodes of wheezing associated with rhinovirus infection or blood eosinophils > or = 0.2 x 10/L.
authors.affiliation: Department of Pediatrics, Turku University Hospital, Turku, Finland. tuomas.jartti@utu.fi
authors.forename: Tuomas
authors.initials: T
authors.lastname: Jartti
authors.forename: Pasi
authors.initials: P
authors.lastname: Lehtinen
authors.forename: Timo
authors.initials: T
authors.lastname: Vanto
authors.forename: Jaakko
authors.initials: J
authors.lastname: Hartiala
authors.forename: Tytti
authors.initials: T
authors.lastname: Vuorinen
authors.forename: Mika J
authors.initials: MJ
authors.lastname: Mäkelä
authors.forename: Olli
authors.initials: O
authors.lastname: Ruuskanen
mesh_terms: D000208:Acute Disease; D002675:Child, Preschool; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D042241:Early Diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D016017:Odds Ratio; D010850:Picornaviridae Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*; D011336:Probability; D012016:Reference Values; D012135:Respiratory Sounds / Q000187:drug effects* / Q000209:etiology; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012229:Rhinovirus / Q000302:isolation & purification*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D011239:Prednisolone